FDA Clears Way for Trial of Gene Editing Therapy for Severe SCD
News
The U.S. Food and Drug Administration (FDA) has cleared the initiation of a Phase 1/2 trial investigating EDIT-301, Editas Medicine’s experimental gene editing cell therapy for sickle cell disease (SCD). ... Read more